ELYM News and Press, Eliem Therapeutics Inc From 02/04/22

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) is fully enrolled Investigational New Drug (IND) application planned in Q1 2022 for ETX-155 Phase 2 trials in major depressive disorder (MDD) and perimenopausal depression (PMD) Patient dosing ...

Eliem Therapeutics (ELYM -18.6%), which had its IPO in August, has fallen to below its IPO price of $12.50 a share. The clinical-stage biotech targets diseases of neurological origin such as chronic pain, psychiatry, and epilepsy. The company expects top-line data in H2 2022 from two mid-stag...

Friday’s COVID-related market selloff had a mixed impact on shares of recent IPOs – with lockdown-sensitive names like fat-removal firm AirSculpt Technologies (NASDAQ:AIRS) sinking, but biotechs like iSpecimen (NASDAQ:ISPC) and in-home fitness firms like Beachbody (NYSE:BODY) ra...

Eliem Therapeutics (NASDAQ:ELYM): Q3 GAAP EPS of -$0.70. Cash, cash equivalents and marketable securities was $169.6M as of September 30, 2021 Press Release For further details see: Eliem Therapeutics reports Q3 results

Advanced ETX-155 clinical development program, with the first subject successfully screened in epilepsy proof-of-concept trial and significant progress made toward the initiation of major depressive disorder (MDD) and perimenopausal depression (PMD) clinical trials Continue...

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorder...

On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months Recently completed an IPO for $92 million in gross proceeds that, along with existing cash, provides cash runway through late 2023 ...

You can read full article here. Drop here! For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Investors will come back from a three-day weekend with an accelerated schedule of corporate events and major industry co...